Colin Dourish

Colin T Dourish PhD DSc is Chief Executive Officer and one of the two founders and owners of P1vital (http://www.p1vital.com/) an innovative Clinical Research and Healthcare Organisation specialising in experimental medicine and novel therapies for CNS disorders, eating disorders and obesity. P1vital and its affiliate company P1vital Products (https://www.p1vitalproducts.com/) provide innovative products and services for pharmaceutical and biotechnology companies developing novel therapies for the treatment of depression, anxiety, schizophrenia, cognitive disorders, eating disorders and obesity. For example, the P1vital^® Oxford Emotional Test Battery (ETB) which was developed in collaboration with Guy Goodwin and Catherine Harmer of the Department of Psychiatry is used to assess the efficacy of novel antidepressants in clinical trials. An online digital health version of ETB, i-spero (https://www.i-spero.com/), has recently been developed for use by physicians in primary care which will transform the treatment of depression by more rapidly detecting antidepressant responses and enabling stratification of patients for more effective therapy.

Dr Dourish has a successful track record in CNS drug discovery and drug development in both major pharmaceutical and biotechnology companies. Prior to co-founding P1vital, he was Senior Vice President Research and CSO of Vernalis, Research Director and co-founder of Cerebrus, Director of Neuropharmacology at Wyeth and Section Head at Merck.

Dr Dourish has over 400 publications in scientific and medical journals and has edited four books in the areas of Psychopharmacology, Neuroscience, Neurology and Psychiatry. Dr Dourish received his BSc in Psychology and his PhD and DSc in Psychopharmacology from the Queen's University of Belfast and carried out postdoctoral research at the University of Saskatchewan in Canada and at the Institute of Neurology in London.